NCT02586051View on ClinicalTrials.gov

A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 19, 2015

Primary Completion Date

November 26, 2018

Study Completion Date

November 26, 2018

Conditions
Kidney Failure, Chronic
Interventions
DRUG

Obinutuzumab

Obinutuzumab 1000 milligrams (mg) IV infusion.

DRUG

Intravenous Immunoglobulin

High dose (2 grams per kilogram \[g/kg\]) IVIG (maximum 140 grams).

Trial Locations (9)

21287

Johns Hopkins Hospital, Baltimore

45219

The Christ Hospital, Cincinnati

University of Cincinnati College of Medicine, Cincinnati

53792

University of Wisconsin, Madison

55905

Mayo Clinic - Minnesota, Rochester

Mayo Clinic, Rochester

90048

Cedars-Sinai Medical Center, Los Angeles

94115

UCSF, San Francisco

94305

Stanford Health Care, Stanford

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02586051 - A Study of Obinutuzumab to Evaluate Safety and Tolerability in Hypersensitized Adult Participants With End Stage Renal Disease Awaiting Transplantation | Biotech Hunter | Biotech Hunter